COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy
 in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on
 therapy 22 months after initial prescription of AVONEX® PS between patients enrolled in the
 current MS AllianceTM program versus patients enrolled in this program prior to October 2007.
Study Design

 Five hundred patients will be enrolled in the prospective portion of the study, all of whom
 will receive AVONEX. Patients will join the study by signing the attached Informed Consent
 Form (Appendix 1) at their doctor's office at the time of prescription. Innomar will provide
 the drug to approximately 40 new patients per month, so it will take about twelve to fourteen
 months to enroll all of the study subjects, assuming that all agree to participate. Once the
 recruitment period is over, it will take another 22 months to complete the study to the
 22-months point for the last subject.

 In the retrospective arm of the study, 500 chart reviews will be completed for patients who
 had participated in the MS Alliance program two (2) to three (3) years ago to determine
 persistence to therapy over a similar 22 month period.

 Study Objectives

 Primary Objectives:

 - To assess patients' compliance (as defined above) with AVONEX therapy in the prospective
 arm using self-reported patients questionnaire, as well as to compare patients' persistence
 on therapy (as defined above) between prospective and retrospective arms.

 Secondary Objective:

 - Evaluate patients' satisfaction with new MSA program.

 Patients and Methods

 Only patients enrolled in the MSA program will be included in this study. There will be no
 interventions above the current standard of care with the MSA program. Two distinct patient
 arms will exist for this study: the prospective arm and the retrospective (chart review) arm.

 Inclusion Criteria

 -  Diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS)

 -  Prescription of AVONEX® PS (prefilled syringes)

 -  Enrolment in the MS AllianceTM program
Inclusion Criteria:

 -  Diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS)

 -  Prescription of AVONEX® PS (prefilled syringes)

 -  Enrolment in the MS AllianceTM program